Search

Search Constraints

You searched for: Author/Creator Daghistani, Doured

Search Results

1. CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS. (9th November 2020)

2. CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. (9th November 2020)

3. CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS. (12th November 2021)

4. CTNI-36. SAFETY OF ONC201 ADMINISTERED TWO CONSECUTIVE DAYS PER WEEK IN PEDIATRIC H3 K27M-MUTANT GLIOMA PATIENTS. (12th November 2021)

5. CTNI-61. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA. (14th November 2022)

6. DIPG-42. CAN WE CHANGE THE LANDSCAPE OF PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)? FIRST DEMONSTRATION OF CLINICAL AND RADIOGRAPHIC RESPONSE IN A PEDIATRIC H3-K27M MUTATED DIPG TO THE DRD2-ANTAGONIST ONC201. Issue 2 (22nd June 2018)

7. DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG. (4th December 2020)

8. HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. (4th December 2020)

9. PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. (11th November 2019)

10. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Issue 1 (13th September 2022)